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bstract
bjective: Shortening of telomere length has been reported in several conditions including Type 2 diabetes and atherosclerosis. The aims of
his study were (1) to assess whether telomere shortening occurs at the stage of pre-diabetes, i.e., impaired glucose tolerance (IGT) and (2)
hether telomere shortening was greater in Type 2 diabetic subjects with atherosclerotic plaques.
ethods: Subjects with impaired glucose tolerance (IGT) (n = 30), non-diabetic control subjects (n = 30), Type 2 diabetic patients without
n = 30) and with atherosclerotic plaques (n = 30) were selected from the Chennai Urban Rural Epidemiology Study (CURES), an ongoing
pidemiological population-based study. Southern-blot analysis was used to determine mean terminal restriction fragment (TRF) length, a
easure of average telomere size, in leukocyte DNA. Levels of thiobarbituric acid reactive substances (TBARS), protein carbonyl content
PCO) and high sensitive C-reactive protein (hs-CRP) were measured by standard methodologies. Carotid intima-media thickness (IMT) was
ssessed by high resolution B-mode ultrasonography.
esults: The mean (±S.E.) TRF lengths were significantly lower in IGT subjects (6.97 ± 0.3 kb; p = 0.002) and lower still in Type 2 diabetic
ubjects without plaques (6.21 ± 0.2; p = 0.0001) and lowest in Type 2 diabetic subjects with atherosclerotic plaques (5.39 ± 0.2; p = 0.0001)
hen compared to control subjects (8.7 ± 0.5). In IGT subjects, TRF length was positively correlated to HDL cholesterol and negatively
orrelated to glycated hemoglobin (HbA1c), TBARS, PCO, HOMA-IR and IMT. In multiple linear regression analysis, presence of diabetes,
DL cholesterol and increased TBARS levels appear as significant determinants of telomere shortening.
onclusion: Telomere shortening is seen even at the stage of IGT. Among subjects with Type 2 diabetes, those with atherosclerotic plaques
ad greater shortening of telomere length compared to those without plaques.
2006 Elsevier Ireland Ltd. All rights reserved.
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. Introduction
Telomeres, composed of large arrays of short guanine-rich
equence, TTAGGG, are essential and dynamic regulators
f cellular life span and chromosome integrity. The biology
f telomeres has long been the focus of numerous investi-
ations related to cancer. However, it is now realized that
elomeres might also play primary or secondary roles in
omplex genetic disorders, including essential hypertension,
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oi:10.1016/j.atherosclerosis.2006.12.003theroscelerosis and diabetes [1–3]. Telomere homeostasis is
egulated through mutually reinforcing mechanisms, such as
ts precise protein composition, telomere length, and telom-
rase activity level. The probability of telomere shortening
ncreases when one or more of these parameters is criti-
ally altered in response to factors such as increased systemic
nflammation and oxidative stress [1,3].
It is well known that increased risk for coronary artery
isease (CAD) is seen not only in subjects with Type 2 dia-
etes but also at the stage of pre-diabetes or impaired glucose
olerance (IGT). This has also been shown for sub-clinical
theroclerosis as measured by carotid intima-medial thick-
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ess (IMT) [4]. We recently demonstrated the occurrence of
elomere shortening in leukocytes from Asian Indian Type 2
iabetic patients [3] thus raising the possibility that telomere
hortening might be a long-term risk marker of diabetes and
acro-vascular complications. There are no studies to our
nowledge that have looked at telomere shortening in pre-
iabetes, i.e., at the stage of IGT. The present goal of this study
as to therefore examine the telomere length in subjects with
GT. Additionally, we also studied Type 2 diabetic subjects
ith and without atherosclerotic plaques (carotid/femoral)
o see whether telomere shortening was greater in Type 2
iabetic subjects with atherosclerosis.
. Subjects and methods
.1. Sample selection
Study subjects were recruited from the Chennai Urban
ural Epidemiology Study (CURES), the methodology of
hich has been published elsewhere [5]. Details such as age,
ex and in diabetic subjects, duration of diabetes and other
etails of diabetic therapy were recorded and clinical exam-
nation was done in all subjects. Subjects with no known
iabetes underwent oral glucose tolerance tests (OGTT)
sing 75 g of oral glucose load (dissolved in 250 ml of water).
hose who were confirmed by OGTT to have 2 h plasma
lucose value <7.8 mmol/l (140 mg/dl) were categorized as
ormal glucose tolerance (NGT) and those with 2 h plasma
lucose value >7.8 mmol/l (140 mg/dl) and <11.1 mmol/l
200 mg/dl) were considered as impaired glucose tolerance
IGT). For the present study we randomly selected (using
omputer generated random numbers) diabetic subjects with-
ut (n = 30) and with atherosclerotic plaques (n = 30), 30
ubjects with IGT and 30 subjects with NGT. The study had
power of 80% to detect a statistically significant (p < 0.05)
ifference of 1.5 kb in TRF length between the study groups.
.2. Clinical and biochemical characterization
Physical examination included height, weight, waist and
ip measurements using standardized techniques. A fast-
ng blood sample was taken and serum separated and
tored at −70 ◦C until the assays were performed. All
iochemical analyses were done on Hitachi-912 Autoanal-
ser (Hitachi, Mannheim, Germany) using kits supplied
y Roche Diagnostics (Mannheim, Germany) [5]. Glycated
aemoglobin (HbA1c) was estimated by high-pressure liq-
id chromatography using the Variant machine (Bio-Rad,
ercules, California, USA). Serum insulin concentration
as estimated using Dako kits (Dako, Glostrup, Denmark).
nsulin resistance was calculated using the Homeostasis
odel Assessment (HOMA-IR) using the formula: fasting
nsulin (IU/ml) × fasting glucose (mmol/l)/22.5. To avoid
he confounding effect of diabetic complications on telom-
ric shortening, the first group of diabetic subjects selected
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ad no evidence of retinopathy (tested by retinal photogra-
hy) or nephropathy (24 h protein excretion <100 mg/day and
rinary albumin levels <30g/mg creatinine). They also had
o history of angina or myocardial infarction and had normal
2 lead resting ECGs. Hypertension was diagnosed if the
ubjects had been treated with antihypertensive drugs or had
ystolic blood pressure (SBP) ≥140 mmHg or diastolic blood
ressure (DBP) ≥90 mmHg. Informed consent was obtained
rom all study subjects and the study was approved by the
nstitutional Ethics Committee.
.3. Assessment of intima-medial thickness (IMT)
Intima-medial thickness (IMT) of the carotid arteries was
etermined using a high resolution B-mode ultrasonography
ystem (logic 400 GE, MILWAUKEE, WI, USA) having an
lectrical linear higher frequency transducer (7.5 MHz). The
MT was measured as the distance from the leading edge
f the first echogenic line to the second echogenic line. The
rst echogenic line represents the lumen intimal interface
nd the second line is produced by the collagen—containing
pper layer of the intimal adventitia. At each longitudinal
rojection, determinations of IMT were conducted at the site
f greatest thickness and at two points 1 cm upstream and
cm downstream from the site of greatest thickness. Details
f the methodology used have been described previously [6].
Imaging of the peripheral arteries of the lower limbs
as done using high-resolution colour duplex ultrasound
LOGIC 400 MD). The lower limb vessels were studied with
he extremities slightly externally rotated and using higher
requency transducers (7.5 MHz) to obtain better image res-
lution. PVD (peripheral vascular disease) was diagnosed if
he stenosis in the artery was greater than 50%.
.4. DNA isolation and TRF length analysis
Blood (2 ml) was mixed with 5 ml of chilled 2× lysis
uffer (10×—0.77 M NH4Cl, 0.46 M K2HCO3), kept in ice
or 20 min and centrifuged at 2000 rpm for 10 min. After
wash with the lysis buffer, the pellet (leukocytes) was
ollected and used for DNA isolation. DNA was isolated
y digestion with proteinase-K and extraction with phe-
ol/chloroform and was quantified spectrophotometrically.
he DNA samples extracted from leukocytes were coded,
nd only after completion of the TRF measurement was the
ode broken for data analysis. Terminal restriction fragment
TRF) lengths were measured as previously described [3].
riefly, equal amounts of DNA (2g) were digested with
estriction enzymes HinfI (20 U) and RsaI (20 U) (Roche
iagnostics, Mannheim, Germany) for 2 h at 37 ◦C. The
RF which determine the telomere lengths were separated
y electrophoresis on 0.8% agarose gel denatured with 0.5 M
aOH/1.5 M NaCl and neutralized for 30 min in 0.5 M Tris
nd 1.5 M NaCl. The DNA was transferred overnight to a
ositively charged nylon membrane using capillary trans-
er. The membranes were then hybridized with telomeric
A. Adaikalakoteswari et al. / Athero
Fig. 1. An autoradiogram showing the lengths of the TRF of genomic DNA;
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wanes 1 and 11: reference samples (high MW and low MW); lane 6: molecular
eight marker (1.9–21.2 kb); other lanes: test samples from study subjects.
robe digoxigenin 3′ end labeled 5′-(CCCTAA)n for 3 h in
he hybridization solution. They were then washed at room
emperature, three times in 2× saline sodium citrate (SSC),
.1% SDS each for 15 min and once in 2× SSC for 15 min.
he digoxigenin labeled probe was detected by digoxigenin
uminescent detection procedure and exposed on X-ray film.
he mean TRF length was determined using automated BIO-
AD Gel documentation software and calculated as follows:
RF =
∑
ODi/(∑ODi/∑MWi), where ODi is optical den-
ity at a given position in the lane and MWi is molecular
eight at that position (Fig. 1). Reproducibility of our method
as checked in blood samples taken twice from the same sub-
ects on two different occasions and validated as described
arlier [4]. The inter-assay coefficient of variation was <3%
nd blot to blot variability was <7%.
.5. CRP measurement
The plasma concentrations of hs-CRP were measured by
highly sensitive nephelometric assay using a monoclonal
ntibody to CRP coated on polystyrene beads (Dade Behring,
arburg, Germany). The intra- and inter-assay coefficient of
ariation for hs-CRP were 4.2 and 6.8%, respectively, and
he lower detection limit was 0.17 mg/l.
.6. Lipid peroxidation
Plasma level of malonodialdehyde (MDA), a marker of
ipid peroxidation was measured by TBARS (thiobarbi-
uric acid reactive substances) by fluorescence methodology
3]. Absolute MDA (malonodialdehyde) levels were calcu-
ated using the regression parameters obtained using various
oncentration (0.25–5.0 nM) of the standard, 1,1′,3,3′,-
a
w
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etramethoxypropane. Inter- and intra-assay coefficient of
ariation were <5 and 10%, respectively.
.7. Protein carbonyls
Carbonyl content was evaluated by the 2,4-dinitrophe-
ylhydrazine (DNPH) assay [7]. Blanks were run with 2 M
Cl alone instead of DNPH reagent. All measurements were
arried out in duplicate. The intra- and inter-assay coefficients
f variation were 2.2 and 2.8%, respectively. Carbonyl con-
ent was expressed in nanomoles per milligram of protein,
sing a molar absorption coefficient of 22,000 M−1 cm−1.
rotein concentration was determined using a standard curve
ith bovine serum albumin (BSA: 0.25–5.0 mg/ml) dissolved
n guanidine hydrochloride and read at 280 nm.
.7.1. Statistical analysis
Comparisons between groups were performed using
npaired Student’s t-test and one-way ANOVA. The criterion
or significance is p < 0.05. Pearson correlation analysis was
one between variables. Risk variables that had significant
ssociation with TRF on univariate regression, were included
s independent variables in multiple linear regression analy-
is. Care was taken to avoid inter-correlated variables in the
egression equation. All analysis was done using Windows
ased SPSS statistical package (Version 10.0, Chicago, IL).
. Results
Table 1 summarizes the characteristics of the study sub-
ects. None of the diabetic patients had ketonuria or any
istory of diabetic ketosis at any time and all were treated
ith oral agents sulphonylurea (glipizide or glibenclamide)
nd/or metformin. Hence they were all diagnosed to have
ype 2 diabetes. Whereas 20 of the diabetic subjects without
therosclerotic plaques and nine with plaques were only on
lucose-lowering agents, 10 diabetic patients without plaques
nd 21 with plaques were on ACE inhibitors and/or statin
r aspirin therapy, in addition to glucose-lowering agents.
iabetic patients with or without atherosclerotic plaques had
ignificantly higher fasting plasma glucose, HbA1c, triglyc-
rides and HOMA-IR compared to control subjects and
mpaired glucose tolerance subjects.
When compared to control subjects (8.7 ± 0.5 kb), the
ean (±S.E.) TRF lengths were significantly lower in IGT
ubjects (6.97 ± 0.3 kb; p = 0.002) and diabetic subjects with-
ut atherosclerotic plaques (6.21 ± 0.2 kb; p = 0.0001) and
till lower in diabetic subjects with atherosclerotic plaques
5.39 ± 0.2 kb; p = 0.0001) (Fig. 2). Age-adjusted telomere
engths were significantly (p = 0.004) shorter in men versus
omen in both control (7.36 ± 0.5 kb versus 10.52 ± 0.9 kb)nd IGT (6.57 ± 0.2 kb versus 8.74 ± 0.7 kb) subjects. There
as no significant gender difference (6.1 ± 0.5 kb versus
.88 ± 0.2 kb) in TFR lengths in diabetic subjects without
therosclerotic plaques. However, in those diabetics with
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Table 1
Clinical characteristics of the study subjects
Parameters Control (n = 30) Impaired glucose
tolerance (n = 30)
Type 2 diabetes without
plaques (n = 30)
Type 2 diabetes with
plaques (n = 30)
Age (years) 49 ± 8 47 ± 9 49 ± 7 63 ± 8*,§,¶
Duration of diabetes (years) – – 3 ± 2 13 ± 6¶
Fasting plasma glucose (mmol/l) 4.6 ± 0.4 5.4 ± 0.7 8.6 ± 3.7*,§ 8.7 ± 0.4*,§
Glycated hemoglobin (%) 5.5 ± 0.6 6.3 ± 1.1 9.4 ± 2.7*,§ 8.6 ± 2.1*,§
Systolic blood pressure (mmHg) 117 ± 11 124 ± 16* 124 ± 24 135 ± 22*,§
Diastolic blood pressure (mmHg) 74 ± 9 80 ± 7* 78 ± 13 79 ± 11*
Body mass index (kg/m2) 23 ± 3 26 ± 3* 25 ± 4* 26 ± 4*
Serum cholesterol (mmol/l) 4.6 ± 0.9 4.8 ± 1.0 5.1 ± 1.1 4.8 ± 1.2
Serum triglycerides (mmol/l) 1.5 ± 0.7 1.8 ± 0.6 2.4 ± 1.2 2.3 ± 1.1
Serum HDL cholesterol (mmol/l) 1.1 ± 0.3 1.0 ± 0.2 1.1 ± 0.3 1.0 ± 0.2
Serum LDL cholesterol (mmol/l) 2.9 ± 0.8 3.1 ± 0.8 3.1 ± 1.0 3.3 ± 0.9
HOMA-IR 1.8 ± 1.1 2.8 ± 1.4 4.2 ± 2.9*,§ 4.8 ± 2.6*,§
IMT (mm) 0.74 ± 0.1 0.77 ± 0.2 0.8 ± 0.2 1.06 ± 0.2*,§¶
TBARS (nm/ml) 6.4 ± 2.5 10.6 ± 5.7* 12.2 ± 6.7* 16.8 ± 6.4*,§¶
PCO (nm/mg protein) 0.6 ± 0.2 0.8 ± 0.2* 1.0 ± 0.3*,§ 1.7 ± 0.5*,§,¶
C ± 2.5* * *,§
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alues are expressed as mean ± S.D.; *p < 0.05 compared to controls; §p < 0
ithout atherosclerotic plaques.
therosclerotic plaques, men had significantly shortened
elomeres than women (4.14 ± 0.3 kb versus 5.2 ± 0.2 kb,
= 0.02).
Compared to control subjects (6.4 ± 0.5 nM/ml), the lev-
ls of TBARS were significantly (p < 0.05) higher in IGT
ubjects (10.6 ± 1.0) and in Type 2 diabetic patients without
12.2 ± 1.2) and with atherosclerotic plaques (16.8 ± 1.2).
CO levels were progressively and significantly (p < 0.05)
ncreased in IGT subjects (0.79 ± 0.04 nM/mg protein) and
n Type 2 diabetic patients without (0.97 ± 0.05) and with
therosclerotic plaques (1.67 ± 0.09) compared to control
ubjects (0.58 ± 0.03). IGT subjects (3.0 ± 0.5 mg/l) and dia-
etics without (3.9 ± 0.6) and with atherosclerotic plaques
5.4 ± 0.7) also exhibited significantly (p < 0.05) higher lev-
ls of CRP, compared to control subjects (1.4 ± 0.2) (Table 1).
To determine whether ACE inhibitor/statin/aspirin thera-
ies interfere with biomarker levels, we analyzed the data
ig. 2. Mean (±S.E.) telomere lengths of (a) control subjects
8.7 ± 0.5 kb); (b) IGT subjects (6.97 ± 0.3 kb); (c) diabetic subjects without
6.21 ± 0.2 kb); (d) with atherosclerotic plaques (5.39 ± 0.2 kb).
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pared to Impaired glucose tolerance; ¶p < 0.05 compared to Type 2 diabetes
elated to TRF length, TBARS, PCO, and CRP levels in
iabetic patients (n = 60) by dividing them into two groups:
hose taking only glucose-lowering agents (group A, n = 29)
nd those taking glucose-lowering agents along with ACE
nhibitor/statin/aspirin (group B, n = 31). No significant dif-
erences in estimated TRF length, TBARS, PCO and CRP
evels were observed (data not shown) and this apparent lack
f change supports the notion that the associated therapy may
ot directly alter biomarker levels in diabetic patients.
Correlation analysis showed that in control subjects the
ge-adjusted TRF length correlated positively with HDL and
egatively with TBARS and PCO levels, IMT and HOMA-
R (Table 2). Similar correlations were seen in IGT subjects
ith an additional negative association between TRF length
nd HbA1c levels. In patients with diabetes, TRF length was
ositively correlated to HDL and negatively correlated to dia-
etes duration, HbA1c, BMI, triglycerides, TBARS, PCO,
RP levels, insulin resistance and IMT.
When age, sex, smoking, presence of diabetes, HbA1c,
BARS, PCO, CRP and HDL cholesterol were included as
otential independent variables in the stepwise regression
nalysis, presence of diabetes (β = −0.696; p = 0.0001), HDL
holesterol (β = 0.067; p = 0.0001) and TBARS (β = −0.092;
= 0.001) independently predicted the TRF length (Table 3).
. Discussion
This study presents three important observations. First, in
sian Indians who are considered more insulin resistant [8]
nd have a higher risk of developing Type 2 diabetes, there
s an association of telomere shortening with impaired glu-
ose tolerance. To the best of our knowledge this is the first
tudy to show telomere shortening in subjects with IGT. Sec-
ndly, Type 2 diabetic subjects with atherosclerotic plaques
A. Adaikalakoteswari et al. / Atherosclerosis 195 (2007) 83–89 87
Table 2
Correlation of age-adjusted TRF with biochemical parameters
Parameters Control subjects (n = 30) Impaired glucose tolerance
subjects (n = 30)
Type 2 diabetes patients with and
without plaques (n = 60)
r p r p r p
Duration of diabetes – – – – −0.63 0.0001
Glycated hemoglobin NS NS −0.44 0.02 −0.31 0.02
Body mass index NS NS NS NS −0.37 0.004
Serum HDL cholesterol 0.44 0.01 0.37 0.04 0.40 0.002
Triglycerides NS NS NS NS −0.27 0.04
HOMA-IR −0.42 0.02 −0.38 0.04 −0.49 0.0001
Intima-media thickness −0.49 0.006 −0.43 0.02 −0.63 0.0001
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-reactive protein NS NS
ad significantly shorter telomeres compared to diabetic sub-
ects without atherosclerotic plaques. Thirdly, shortening of
elomeres was associated with increased markers of systemic
nflammation and oxidative stress.
Telomere shortening has recently been shown to occur in
any age-related diseases [1,3,9]. The association between
hortened telomeres and IGT observed in this study is of
articular interest. An increased predisposition to diabetes
nd coronary artery disease (CAD) among Asian Indians has
ong been recognized and claimed to stem in most part from
GT [10]. The higher rates of CAD and Type 2 diabetes
mong Indians are also often not explained by traditional
isk factors. Therefore, telomere shortening may represent
non-traditional risk factor and long-term biomarker to be
ssociated with IGT and in the natural history of diabetes and
ardiovascular diseases. One problem with this claim is that
ncreased leukocyte turnover in ‘inflammatory’ IGT subjects
ight have produced a confounding effect, i.e., more cell
ivisions in leukocyte populations could have contributed
o telomere shortening. However, this may not be wholly
rue, as there was no correlation between CRP levels and
elomere length in IGT subjects, and in a logistic regression
nalysis, CRP levels did not affected the association of IGT
ith telomere shortening. Similarly, markers of inflamma-
ion have not affected the association of shorter telomeres
ith risk of myocardial infarction [11]. Therefore, the shorter
elomeres observed in WBCs from IGT subjects may not
eflect simply an epiphenomenon. Referring to the recent
iterature, it appears that telomere attrition is strongly cor-
elated with insulin resistance (IR) [12,13]. Moreover, it was
nferred from the Framingham Heart Study that shorter leuko-
able 3
ultivariate regression analysis for the association of telomere restriction
ragment (TRF) length in study subjects
odel TRF Unstandardized coefficients
β Standard error Significance
iabetic group −0.696 0.160 0.0001
DL 0.067 0.016 0.0001
BARS −0.092 0.028 0.001
r
e
p
e
m
B
s
i
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t
c−0.36 0.05 −0.49 0.0001
−0.46 0.01 −0.63 0.0001
NS NS −0.49 0.0001
yte telomere length in hypertensives is largely due to insulin
esistance [14]. There is increasing evidence to suggest that
R, a predecessor for both CAD and diabetes, is associated
ith chronic low-grade inflammation and oxidative stress
15]. There might be a continuous genesis of oxidative stress
nd inflammation in the natural history of diabetes with its
erturbations starting as early as IGT [16,17]. Therefore, it is
lausible to suggest that these factors could mechanistically
onnect insulin resistance and impaired glucose tolerance
ith changes in telomere length. This view is supported by
ur study in which telomere shortening in subjects with IGT
as associated with insulin resistance, increased lipid perox-
dation and protein carbonyl levels.
This study reconfirms our earlier work [3] that patients
ith Type 2 diabetes have telomere shortening. A recent study
ends support to our observations that monocytes telomere
engths were significantly shorter in Type 2 diabetic sub-
ects compared to control subjects [9]. While our studies
present and Ref. [3]) demonstrated an association of telom-
re shortening with systemic markers of oxidative stress (lipid
eroxidation and protein oxidation) in Type 2 diabetes, the
tudy by Sampson et al [9] also showed an association of
elomere shortening and oxidative DNA damage. However,
nlike our study, the telomere shortening observed by the
uropean group was independent of glycemic control, IR and
nflammatory markers [9]. The strong association of telom-
re shortening and IR shown in our study could imply a role
f ethnicity as Indians have been shown to be more insulin
esistant compared to their European counterparts [8].
Another important observation in this study is that telom-
re length was shorter in diabetic subjects with atherosclerotic
laques compared to their counterparts without plaques. Sev-
ral studies have proposed that telomere shortening is a
arker of biological ageing and atherosclerosis [18–20].
enetos et al [1] have showed that shorter telomere was a
ignificant predictor of the presence of carotid artery plaques
n hypertensive subjects. Increased telomere shortening and
MT in diabetic patients with atherosclerotic plaques in our
tudy clearly indicate a role for vascular senescence. Shorter
elomeres have been demonstrated in coronary endothelial
ells of patients with coronary heart disease [2] and, degen-
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rative aortic valve stenosis was also shown associated with
horter telomere length in the elderly [21]. Senescence in
ascular smooth muscle cells (VSMCs) in atherosclerotic
laques was recently shown related to telomere shortening
22] and combining an in vitro work, this study concluded
hat human atherosclerosis was characterized by senescence
f VSMCs, accelerated oxidative DNA damage, inhibition
f telomerase and marked telomere shortening. A Japanese
tudy also demonstrated that telomere shortening could be
nvolved in the development of atherosclerotic disease in
atients with hypercholesterolemia and diabetes [23]. Given
hat patients with high blood glucose are at an increased risk
or cardiovascular disease, the results of our study suggest
hat in the presence of chronic hyperglycemia, shorter telom-
re in WBCs might serve as a biological indicator of increased
redilection to carotid artery atherosclerosis.
While numerous studies have linked oxidative stress as a
ommon denominator at the crossroad of insulin resistance,
iabetes and cardiovascular diseases [7,16,24,25], oxidative
tress is also considered as a common trigger for accelerated
elomere shortening. The GGG-specific telomere sequence
elative to rest of the chromosome has been shown highly sus-
eptible to oxidative stress [26]. As we reported in this study,
xidative damage in macromolecules (lipid, protein, DNA)
een in various disease states correlates well with telomere
hortening [1,3,9,14]. In our earlier study we showed that hs-
RP has a strong association with diabetes and CAD [27].
he present work reveals an additional association between
s-CRP and telomere shortening in Type 2 diabetes. Since
ncreased hs-CRP is a reflection of an inflammatory milieu
nd pro-oxidant effects of CRP are known [28], inflammation
nd oxidative stress might have synergistic effect on telomere
hortening. Whatever may be the causes of telomere short-
ning, it would be important for the future studies to look for
heir impact on the regenerating and/or functional capacity
f insulin-responsive tissues (pancreas, adipose and muscle).
ndeed, premature telomere shortening and impaired regen-
rative response has been recently shown in hepatocytes of
ndividuals with nonalcoholic fatty liver disease [29].
The positive association of HDL cholesterol and telom-
re length in our study also deserves special mention. It has
een shown that increased HDL cholesterol and telomere
ength were linked to increased longevity in animal mod-
ls and humans [30]. Low levels of HDL cholesterol are
onsidered as one of the components of ‘atherogenic dyslipi-
emia’ [31] and low HDL cholesterol phenotypes have been
ecently shown to display elevated oxidative stress, attenu-
ted antioxidative activity [32] and accelerated senescence
33].
In non-diabetic subjects, the age-adjusted telomere length
s shorter in men than in women, confirming earlier stud-
es [3,34,35]. This trend was persistently seen in subjects
ith IGT also, as reported in this study for the first time.
s premenopausal women are less prone than men to car-
iovascular diseases and several systemic parameters show
oor correlation with blood pressure in women, our observa-sclerosis 195 (2007) 83–89
ions suggest that the biology of ageing differs between men
nd women. We suggest that the enigmatic gender difference
n telomere shortening and the natural history of diabetes
eed to be explored by longitudinal studies. Such studies are
mportant because (a) estrogen is a potent anti-inflammatory
nd antioxidant agent; (b) there is an estrogen-response ele-
ent present in hTERT [36]; (c) hormonal changes in women
re expected to have drastic influences on insulin resistance,
diposity, oxidative stress and telomere length.
While Type 2 diabetes arise from the interaction of genetic
redisposition and environmental factors, telomere length
ppears to be a reliable biomarker as it too influenced by
enetic and environmental triggers. As telomere length is also
ighly heritable [37], probably X-linked in some cases [35],
aternally inherited [38], mapped to a major locus on chro-
osome 12 [39] and considered as quantitative trait [40], the
ole of genetic predisposition to short telomeres in diabetes
nd associated disorders needs further investigations.
Being a cross-sectional one, our study cannot explain a
ause and effect relationship of telomere shortening with
iabetes development or progression to atherosclerosis.
ssessing whether telomere erosion is an independent risk
actor for IGT, Type 2 diabetes or proneness to atherosclerosis
mong diabetic subjects would require prospective studies.
evertheless, because telomere shortening appears as a long-
erm biomarker, it would be interesting to see whether tight
ontrol of diabetes could halt or minimize this process.
In conclusion, our study shows that telomere shortening
ccurs in subjects with IGT (pre-diabetes) and is progres-
ively greater in subjects with Type 2 diabetes and those
ith diabetes and atherosclerosis. As more data accumulates
egarding telomere dynamics in the regulation of cell cycle
vents and cellular dysfunction in insulin-responsive target
issues, therapeutic opportunities may develop to prevent
elomere shortening.
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